This could be a game changer. Marketcap of Lexicon Pharm that produces Inpefa is only $538M with plenty of cash on hand. Competitor drugs Jardiance from NYSE:LLY and Farxiga from NASDAQ:AZN did over $6B and $4B revenue respectively in 2022 and expected to grow quite a bit over the next few years. Inpefa received FDA approval and was rolling out...
They announced positive top line results from their P3 trial. Adolescent and paediatric trials are happening both this month and next. Major competitors such as NYSE:JNJ , NYSE:PFE , NYSE:NVS that require multiple pills a day for the same effect. Extremely large TAM. Buyout candidate? We have popped off of the bottom channel and are looking for 1.10. A...